Inflammation and Immune-Based Scores Predict Prognosis for Patients with Hepatocellular Carcinoma: A Pilot Single-Center Study
Authors:
- Merve Guzel DirimMDMerve Guzel Dirim
- Asli Cifcibasi OrmeciAOAsli Cifcibasi Ormeci
- Bilger CavusBCBilger Cavus
- Arzu PoyanliAPArzu Poyanli
- Kursat Rahmi SerinKSKursat Rahmi Serin
- Filiz AkyuzFAFiliz Akyuz
- Kadir DemirKDKadir Demir
- Selman Fatih BesisikSBSelman Fatih Besisik
- Sabahattin KaymakogluSKSabahattin Kaymakoglu
Open Access
- 6 January 2025
- journal article
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 36 (4) , 219-228
Abstract
Background/Aims: Hepatocellular carcinoma (HCC) ranks as a major contributor to cancer-related deaths. Systemic inflammation plays a pivotal role in HCC development and progression. Thus, we aimed to determine the impact of inflammation- and immune-based scores in predicting the prognosis of HCC. Materials and Methods: In this retrospective study, patients with HCC were enrolled between 2010 and 2020. The purpose of this ret rospective study was to evaluate the impact of various biomarkers, including baseline alpha fetoprotein (AFP) levels, C-reactive protein (CRP) –albu min–l ympho cyte (CALLY) index, neutrophil-to-CRP (N/CRP) ratio, systemic immune-inflammation index (SII), albumin–bili rubin (ALBI) score, neutr ophil -to-l ympho cyte ratio (NLR), and aspartate aminotransferase (AST)-to-alanine aminotransferase (ALT) (AST/ALT) ratio (AAR), on survival, invasion of vascular tracts, metastasis, and treatment responses. Results: A total of 199 patients with complete (n = 44) and non-complete (n = 145) treatment response groups were enrolled in the study. All scores for the non-complete response group were statistically significant (P < .05). The areas under the curves for predicting a non-complete response group were 0.651, 0.649, 0.636, 0.625, 0.613, 0.609, and 0.600 for AFP, CALLY index, AAR, SII, N/CRP ratio, ALBI score, and NLR, respectively. These results are consistent with the assessment of mortality and HCC progression. Conclusion: Our results indicate that these biomarkers could serve as powerful prognostic tools for HCC. Cite this article as: Guzel Dirim M, Cifcibasi Ormeci A, Cavus B, et al. Inflammation and immune-based scores predict prognosis for patients with hepatocellular carcinoma: A pilot single-center study. Turk J Gastroenterol. 2025;36(4):219-228.Keywords
This publication has 25 references indexed in Scilit:
- Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinomaHepatobiliary & Pancreatic Diseases International, 2015
- Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular CarcinomaClinical Cancer Research, 2014
- The C-Reactive Protein/Albumin Ratio, a Novel Inflammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular CarcinomaAnnals of Surgical Oncology, 2014
- Albumin Suppresses Human Hepatocellular Carcinoma Proliferation and the Cell CycleInternational Journal of Molecular Sciences, 2014
- The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancerCancer Treatment Reviews, 2013
- Circulating stem cell–like epithelial cell adhesion molecule–positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resectionHepatology, 2012
- Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinomaMedical Oncology, 2012
- Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinomaHepatology, 2011
- The place of downstaging for hepatocellular carcinomaJournal of Hepatology, 2010
- Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patientsJournal of Hepatology, 2010